Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyClover Health Cyramza Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentClover HealthPolicy 4198-A

    Standard Medicare Part B Management Cyramza

    Customize your policy alerts

    Sign up for clover_health Policy 4198-A alerts

    Get alerted when Policy 4198-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and continued coverage of Cyramza for Medicare Part B members across FDA-approved and specified compendial oncology indications, including gastric, esophageal, lung, colorectal, hepatocellular, mesothelioma, thymic, and urothelial cancers.

    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Cyramza
    Policy CodePolicy 4198-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFor initial requests, provide EGFR mutation testing and alpha fetoprotein results when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    9Cancer indication categories
    12 moInitial authorization duration
    12 moContinuation authorization duration
    ≥400 ng/mLHepatocellular carcinoma AFP threshold
    FDA + compendial

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage scope

    Covered Indications and Continuation Therapy

    Gastric, GEJ, EGJ, and esophageal adenocarcinoma

    Covered when all of the following criteria are met:

    Disease setting and treatment

    • Disease status

      • Member is not a surgical candidate.
      • Disease is unresectable, locally advanced, recurrent, or metastatic.
    • Subsequent regimen

      • Cyramza is used as a single agent as subsequent therapy.
      • Cyramza is used in combination with paclitaxel as subsequent therapy.
      • Cyramza is used in combination with irinotecan, with or without fluorouracil, as subsequent therapy.

    Non-small cell lung cancer

    Covered when either of the following criteria is met:

    NSCLC treatment options

    • Docetaxel combination: Member has recurrent, advanced, or metastatic NSCLC, and Cyramza is used in combination with docetaxel as subsequent therapy.
    • Erlotinib combination: Member has recurrent, advanced, or metastatic NSCLC, and Cyramza is used in combination with erlotinib as first-line therapy for EGFR exon 19 deletion or exon 21 (L858R) substitution mutation-positive disease.EGFR exon 19 deletion or exon 21 (L858R) substitution mutation

    Colorectal cancer

    Covered when either of the following criteria is met:

    Colorectal cancer treatment options

    • Advanced or metastatic disease: Cyramza is used in combination with FOLFIRI or irinotecan for advanced or metastatic colorectal cancer, including anal adenocarcinoma and appendiceal adenocarcinoma.
    • Adjuvant treatment: Cyramza is used in combination with FOLFIRI or irinotecan as adjuvant treatment for unresectable metachronous metastases that converted to resectable disease after initial treatment.

    Hepatocellular carcinoma

    Covered when all of the following criteria are met:

    • Member has progressive hepatocellular carcinoma.
    • Cyramza is used as subsequent treatment and as a single agent.
    • Member has an alpha fetoprotein (AFP) level greater than or equal to 400 ng/mL.AFP ≥ 400 ng/mL

    Mesothelioma

    Covered when all of the following criteria are met:

    • Eligible disease site

      • Member has pleural mesothelioma.
      • Member has pericardial mesothelioma.
      • Member has tunica vaginalis testis mesothelioma.
    • Cyramza is used in combination with gemcitabine as subsequent treatment.

    Thymic carcinoma

    Covered when any of the following criteria is met:

    Thymic carcinoma treatment options

    • Recurrent, advanced, or metastatic disease: Member has recurrent, advanced, or metastatic disease, and Cyramza is used as first-line therapy in combination with carboplatin and paclitaxel and continued as single-agent maintenance therapy.
    • R1 or R2 resection: Member has had an R1 or R2 resection, and Cyramza is used in combination with carboplatin and paclitaxel as postoperative treatment.R1 or R2 resection
    • Preoperative treatment: Member has surgically resectable disease, R0 resection is considered uncertain, and Cyramza is used in combination with carboplatin and paclitaxel as preoperative treatment.

    Urothelial carcinoma

    Covered when all of the following criteria are met:

    • Member has advanced or metastatic urothelial carcinoma.
    • Cyramza is used in combination with docetaxel.
    • Disease progressed within 12 months after platinum-containing chemotherapy.Disease progression within 12 months after platinum-containing chemotherapy

    Continuation therapy — NSCLC

    For NSCLC continuation, all of the following criteria must be met:

    NSCLC continuation

    • Member is currently receiving therapy with Cyramza.
    • Cyramza is being used to treat non-small cell lung cancer.
    • Benefit from therapy

      • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
      • Disease is T790M negative and there is no evidence of unacceptable toxicity while on the current regimen.T790M negative

    Continuation therapy — all other indications

    For continuation of all other indications, all of the following criteria must be met:

    Continuation for all other indications

    • Member is currently receiving therapy with Cyramza.
    • Cyramza is being used to treat an indication listed in the coverage criteria section.
    • Benefit from therapy

      • There is no evidence of unacceptable toxicity while on the current regimen.
      • There is no evidence of disease progression while on the current regimen.

    Continuation Therapy — All Other Indications

    Continuation authorization for all other indications may be granted for 12 months when all of the following criteria are met:

    Continuation of therapy

    • Current treatment and covered indication

      • Member is currently receiving therapy with Cyramza.
      • Cyramza is being used to treat an indication listed in the coverage criteria section.
    • Clinical benefit

      • There is no evidence of unacceptable toxicity while on the current regimen.
      • There is no evidence of disease progression while on the current regimen.

    Clinical Coding and Biomarker Reference

    Alpha Fetoprotein Threshold
    BiomarkerAlpha fetoprotein (AFP)
    Required thresholdGreater than or equal to 400 ng/mL
    Applicable useSubsequent single-agent treatment of progressive hepatocellular carcinoma

    Authorization, Documentation, and Denial Considerations

    Prior Authorization

    Obtain initial authorization for listed cancers

    Prior authorization may be granted for 12 months when the member meets the applicable disease-specific coverage criteria for gastric, gastro-esophageal junction, esophagogastric junction, and esophageal adenocarcinoma; non-small cell lung cancer; or colorectal cancer.

    Prior Authorization

    Obtain authorization for additional indications

    Prior authorization may be granted for 12 months when the member meets the applicable disease-specific criteria for hepatocellular carcinoma, mesothelioma, thymic carcinoma, or urothelial carcinoma.

    Prior Authorization

    Document current treatment and benefit

    Continuation authorization requires that the member is currently receiving Cyramza and is receiving benefit from therapy under the applicable NSCLC or other-indication continuation criteria.

    Policy Background

    Cyramza (ramucirumab) is managed under this Medicare Part B policy for covered FDA-approved indications and specified compendial oncology uses. Coverage addresses advanced, metastatic, recurrent, progressive, and selected perioperative or maintenance treatment settings across gastric, gastro-esophageal junction, esophagogastric junction, esophageal, lung, colorectal, hepatocellular, mesothelioma, thymic, and urothelial cancers. Treatment may be administered as monotherapy or in combination with chemotherapy or targeted therapy, depending on the disease and treatment setting.

    FDA-approved uses are supported by the Cyramza prescribing information. Specified additional uses are supported primarily by the NCCN Drugs and Biologics Compendium, with urothelial carcinoma supported by Micromedex DrugDex. Requests for indications not listed in the coverage criteria require individual assessment and supporting evidence from Medicare-approved compendia.

    Continuation Therapy Definitions

    Benefit From Therapy
    Applies toContinuation therapy
    Toxicity requirementNo evidence of unacceptable toxicity while on the current regimen
    Progression requirementNo evidence of disease progression while on the current regimen; for NSCLC, an alternative pathway permits T790M-negative disease with no unacceptable toxicity
    Benefit
    DefinitionBenefit from therapy means no evidence of unacceptable toxicity while on the current regimen and no evidence of disease progression while on the current regimen
    ToxicityNo evidence of unacceptable toxicity on the current regimen

    Treatment Line Requirements

    First-line

    Cyramza is covered in the following first-line settings when the applicable disease-specific criteria are met:

    First-line treatment settings

    • First-line Cyramza in combination with erlotinib for EGFR exon 19 deletion or exon 21 (L858R) substitution mutation-positive metastatic or recurrent/advanced NSCLC.
    • First-line Cyramza in combination with carboplatin and paclitaxel for recurrent, advanced, or metastatic thymic carcinoma, followed by single-agent maintenance therapy.

    Second-line

    Cyramza is covered as subsequent therapy in the following settings when the applicable disease-specific criteria are met:

    Subsequent treatment settings

    Biomarker and Molecular Testing Requirements

    EGFR Mutation Requirement
    BiomarkerEGFR exon 19 deletion or exon 21 (L858R) substitution mutation
    Required statusPositive mutation status
    Applicable treatmentFirst-line Cyramza in combination with erlotinib for metastatic, recurrent, or advanced NSCLC
    EGFR or ALK Genomic Tumor Aberrations
    Tumor aberrationsEGFR or ALK genomic tumor aberrations
    Required prior treatment outcomeDisease progression on FDA-approved therapy for the aberration is required before receiving Cyramza
    Applicable treatment

    Covered Treatment Regimens and Evidence-Supported Uses

    IndicationCovered regimen
    Gastric, GEJ, EGJ, and esophageal adenocarcinomaSingle agent; in combination with paclitaxel; or in combination with irinotecan with or without fluorouracil.
    IndicationCovered regimen
    Non-small cell lung cancer (NSCLC)In combination with docetaxel as subsequent therapy; or in combination with erlotinib as first-line therapy for EGFR exon 19 deletion or exon 21 (L858R) substitution mutation-positive disease.
    IndicationCovered regimen
    Colorectal cancerIn combination with FOLFIRI or irinotecan for advanced or metastatic disease, or as adjuvant treatment for unresectable metachronous metastases converted to resectable disease after initial treatment.
    IndicationCovered regimen
    Hepatocellular carcinomaSingle agent for subsequent treatment of progressive disease when AFP is ≥400 ng/mL.
    IndicationCovered regimen
    Pleural, pericardial, or tunica vaginalis testis mesotheliomaIn combination with gemcitabine as subsequent treatment.
    IndicationCovered regimen
    Thymic carcinomaIn combination with carboplatin and paclitaxel, with possible continuation as single-agent maintenance therapy.
    IndicationCovered regimen
    Urothelial carcinomaIn combination with docetaxel.
    IndicationCovered use
    FDA-approved indicationsCyramza used according to the manufacturer's prescribing information.
    IndicationCompendia-supported use
    Colorectal cancerCyramza in combination with irinotecan; supported uses include anal adenocarcinoma, appendiceal adenocarcinoma, advanced disease, and adjuvant treatment.
    IndicationCompendia-supported use
    Gastric, GEJ, EGJ, and esophageal adenocarcinomaCyramza for gastric, gastro-esophageal junction, esophagogastric junction, and esophageal adenocarcinoma as supported by the cited compendia.
    IndicationCompendia-supported use
    Recurrent advanced NSCLCCyramza for recurrent, advanced non-small cell lung cancer as supported by the cited NCCN compendium.
    IndicationCompendia-supported use
    Anal adenocarcinoma, appendiceal adenocarcinoma, hepatocellular carcinoma, mesothelioma, and thymic carcinomaCyramza for the listed indications as supported by the cited NCCN compendium.
    IndicationCompendia-supported use
    Urothelial carcinomaCyramza for urothelial carcinoma as supported by the Micromedex DrugDex database.
    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Cyramza
    Policy CodePolicy 4198-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFor initial requests, provide EGFR mutation testing and alpha fetoprotein results when applicable.
    SourceLink
    On This Page
    Covered Indications and Continuation TherapyClinical Coding and Biomarker ReferenceAuthorization, Documentation, and Denial ConsiderationsPolicy BackgroundContinuation Therapy DefinitionsTreatment Line RequirementsBiomarker and Molecular Testing RequirementsCovered Treatment Regimens and Evidence-Supported Uses
    • Benefit requires no applicable unacceptable toxicity or disease progression on the current regimen.
    • For NSCLC, benefit may also be established when disease is T790M negative with no evidence of unacceptable toxicity.
    Prior Authorization

    Meet the 12-month continuation requirements

    For continuation of therapy under other indications, authorization for 12 months may be granted only when the member is currently receiving Cyramza, the medication is being used for an indication listed in the coverage criteria, and the member is benefiting from therapy.

    • Benefit requires no evidence of unacceptable toxicity while on the current regimen.
    • Benefit also requires no evidence of disease progression while on the current regimen.
    Documentation Required

    Keep required clinical results available

    For initial requests, EGFR mutation testing results and alpha fetoprotein (AFP) level results, where applicable, must be available upon request.

    • Provide EGFR mutation testing results when applicable.
    • Provide AFP level results when applicable.
    Documentation Required

    Include compendia support for other indications

    Requests for indications not listed in the criteria must include supporting evidence from Medicare-approved compendia.

    Prior Authorization

    Support an unlisted indication

    Indications other than those listed in the criteria require individual assessment and supporting evidence from Medicare-approved compendia.

    Denial Risk

    Verify criteria and exclusions before submitting

    Coverage requires that all applicable approval criteria are met and that the member has no exclusions to the prescribed therapy. Failure to satisfy an applicable criterion or the presence of an exclusion may result in noncoverage.

    Denial Risk

    Prevent continuation denial

    Continuation requests require that the member is currently receiving Cyramza and is receiving benefit from therapy without the applicable unacceptable toxicity or disease progression.

    • Confirm current treatment with Cyramza.
    • Document benefit on the current regimen.
    Denial Risk

    Avoid continuation denial conditions

    Continuation authorization may be denied when the member is not currently receiving Cyramza, the medication is not being used for an indication listed in the coverage criteria, or the member is not benefiting from therapy because of unacceptable toxicity or disease progression.

    Disease status
    No evidence of disease progression on the current regimen
    Subsequent therapy for gastric, GEJ, EGJ, or esophageal adenocarcinoma in an eligible disease setting, using Cyramza as a single agent or in combination with paclitaxel or irinotecan with or without fluorouracil.
  1. Subsequent therapy with Cyramza in combination with docetaxel for recurrent, advanced, or metastatic NSCLC.
  2. Subsequent single-agent Cyramza for progressive hepatocellular carcinoma with AFP greater than or equal to 400 ng/mL.
  3. Subsequent Cyramza in combination with gemcitabine for pleural, pericardial, or tunica vaginalis testis mesothelioma.
  4. Cyramza in combination with docetaxel for advanced or metastatic urothelial carcinoma with disease progression within 12 months after platinum-containing chemotherapy.
  5. Salvage

    Cyramza may be covered in the following salvage, perioperative, or maintenance settings when the applicable disease-specific criteria are met:

    Salvage and related treatment settings

    • Adjuvant Cyramza in combination with FOLFIRI or irinotecan for unresectable metachronous colorectal cancer metastases that converted to resectable disease after initial treatment.
    • Postoperative Cyramza in combination with carboplatin and paclitaxel for thymic carcinoma after an R1 or R2 resection.
    • Preoperative Cyramza in combination with carboplatin and paclitaxel for surgically resectable thymic carcinoma when R0 resection is considered uncertain.
    • Single-agent Cyramza maintenance after first-line combination therapy with carboplatin and paclitaxel for recurrent, advanced, or metastatic thymic carcinoma.
    Cyramza in combination with docetaxel for metastatic NSCLC
    AFP Requirement
    BiomarkerAlpha fetoprotein (AFP)
    Required thresholdGreater than or equal to 400 ng/mL
    Applicable treatmentSubsequent single-agent treatment of progressive hepatocellular carcinoma
    T790M Status
    BiomarkerT790M
    Required statusDisease is T790M negative
    Applicable settingNSCLC continuation therapy benefit definition